AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Analyst Recommendations
This is a summary of current ratings and price targets for AbCellera Biologics and Pluri, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AbCellera Biologics | 1 | 1 | 6 | 2 | 2.90 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
AbCellera Biologics presently has a consensus target price of $16.33, indicating a potential upside of 31.09%. Given AbCellera Biologics’ stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Pluri.
Risk & Volatility
AbCellera Biologics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
Profitability
This table compares AbCellera Biologics and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AbCellera Biologics | -248.83% | -17.49% | -12.36% |
| Pluri | -2,344.59% | N/A | -82.71% |
Valuation & Earnings
This table compares AbCellera Biologics and Pluri”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AbCellera Biologics | $75.13 million | 50.85 | -$146.41 million | ($0.54) | -23.07 |
| Pluri | $1.02 million | 13.85 | -$23.82 million | ($2.45) | -0.46 |
Pluri has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Comparatively, 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
AbCellera Biologics beats Pluri on 11 of the 15 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
About Pluri
Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
